Literature DB >> 1680817

Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice.

A M Wärri1, A M Laine, K E Majasuo, K K Alitalo, P L Härkönen.   

Abstract

Amplification and enhanced expression of the erbB2/HER-2/neu gene has been associated with an increased growth rate and poor prognosis of human breast cancer. We have studied the relationship between erbB2 expression and the regulation of cell growth by estrogen and anti-estrogens in the human breast cancer cell line ZR-75-1 in vitro and in athymic nude mice, pS2 being used as a marker gene for estrogen-stimulated gene expression. Only low amounts of erbB2 mRNA were seen in the cells grown in vitro in the presence of estrogen which stimulated the cells to proliferate rapidly and induced the expression of pS2 mRNA. Upon hormone withdrawal, erbB2 mRNA and protein increased, while pS2 mRNA declined to an undetectable level and cell proliferation slowed down. Opposite but more rapid changes were observed upon estrogen addition. The anti-estrogens toremifene and tamoxifen inhibited estrogen induction of pS2 expression, down-regulation of erbB2 expression and proliferation of the ZR-75-I cells in a concentration-dependent manner. Similar results were obtained in nude mice. ZR-75-I cells formed tumors only in mice carrying estrogen pellets. In these tumors little erbB2 mRNA was seen. Concomitant administration of toremifene or tamoxifen increased erbB2 mRNA and abolished pS2 mRNA. Our results show that enhanced expression of erbB2 is associated with hormone deprivation and growth arrest of the estrogen-dependent breast cancer cell line ZR-75-I. Thus, in mammary epithelial cells, erbB2 may have important estrogen-regulated functions which are not related to cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1680817     DOI: 10.1002/ijc.2910490425

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle.

Authors:  A Gompel; A Martin; P Simon; D Schoevaert; G Plu-Bureau; D Hugol; J Audouin; E Leygue; J B Truc; P Poitout
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 2.  Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland.

Authors:  M De Bortoli; C Dati
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 3.  Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.

Authors:  P Nagy; A Jenei; S Damjanovich; T M Jovin; J Szölôsi
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

4.  Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry.

Authors:  T van Agthoven; M Timmermans; J A Foekens; L C Dorssers; S C Henzen-Logmans
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

5.  Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.

Authors:  M Hauglid Flågeng; L L Haugan Moi; J M Dixon; J Geisler; E A Lien; W R Miller; P E Lønning; G Mellgren
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

6.  STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro.

Authors:  Xiaoyan Wang; Guozhu Wang; Yi Zhao; Xiaoan Liu; Qiang Ding; Jingping Shi; Yin Ding; Shui Wang
Journal:  J Biomed Res       Date:  2012-04-18

7.  Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.

Authors:  I Soubeyran; N Quénel; L Mauriac; M Durand; F Bonichon
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

8.  Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer.

Authors:  H J van Slooten; B A Bonsing; A J Hiller; G T Colbern; J H van Dierendonck; C J Cornelisse; H S Smith
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

9.  Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas.

Authors:  H Naundorf; K Parczyk; W Zschiesche; S Reinecke; B Büttner; G J Saul; B Sinn; I Fichtner
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.322

10.  Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.

Authors:  Abby L Cosentino-Boehm; Jacqueline M Lafky; Tammy M Greenwood; Kimberly D Kimbler; Marites C Buenafe; Yuxia Wang; Adam J Branscum; Ping Yang; Nita J Maihle; Andre T Baron
Journal:  Diagnostics (Basel)       Date:  2013-01-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.